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Abstract
Rationale: Nasal allergen provocations may be useful in investigating the patho-
physiology of allergic rhinitis and effects of treatments.
Objective: To use grass pollen nasal allergen challenge (NAC) to investigate the
effects of allergen immunotherapy in a cross-sectional study.
Methods: We studied nasal and cutaneous responses in untreated subjects with
seasonal grass-pollen allergic rhinitis (n = 14) compared with immunotherapy-
treated allergics (n = 14), plus a nonatopic control group (n = 14). Volunteers
underwent a standardized NAC with 2000 biological units of timothy grass aller-
gen (equivalent to 1.3 lg major allergen, Phl p5). Nasal fluid was collected and
analysed by ImmunoCAP and multiplex assays. Clinical response was assessed by
symptom scores and peak nasal inspiratory flow (PNIF). Cutaneous response was
measured by intradermal allergen injection. Retrospective seasonal symptom
questionnaires were also completed.
Results: Immunotherapy-treated patients had lower symptom scores (P = 0.04)
and higher PNIF (P = 0.02) after challenge than untreated allergics. They had
reduced early (P = 0.0007) and late (P < 0.0001) skin responses, and lower retro-
spective seasonal symptom scores (P < 0.0001). Compared to untreated allergics,
immunotherapy-treated patients had reduced nasal fluid concentrations of IL-4,
IL-9 and eotaxin (all P < 0.05, 8 h level and/or area under the curve compari-
son), and trends for reduced IL-13 (P = 0.07, area under the curve) and early-
phase tryptase levels (P = 0.06).
Conclusions: Nasal allergen challenge is sensitive in the detection of clinical and
biological effects of allergen immunotherapy and may be a useful surrogate mar-
ker of treatment efficacy in future studies.
Allergic rhinitis is common, troublesome, costly and associ-
ated with asthma (1–3). Specific allergen immunotherapy is
an effective treatment (4), particularly for seasonal allergic
rhinitis. Clinical trials of allergen immunotherapy face sev-
eral challenges, including standardization of allergen expo-
sure between individuals, seasons and locations.
Additionally, the primary outcome – combined symptom
and medication score – may be subject to poor compliance,
the result being that large numbers of participants are typi-
cally required.
We have previously described nasal challenges with grass
pollen, accompanied by collection and analysis of mediators
in nasal fluid (5). Response to nasal challenge may serve as a
surrogate for seasonal symptoms (6), allowing assessment
outside of pollen seasons, control of doses, and real-time
recording of symptoms. As such, nasal challenges and, more
recently, environmental exposure chambers have been used
to assess responses to allergen immunotherapy (7, 8). The
effects of allergen immunotherapy on mediators in nasal fluid
have also been investigated, with regard to ragweed (9), cat
dander (7), grass pollen (10) and silver birch pollen (11),
demonstrating suppression of histamine (9), kinins (12), tryp-
tase, eosinophil cationic protein (ECP) (10) and IL-5 (11).
Combining clinical and immunological outcomes has the ben-
efit of providing insight into the mechanisms of allergic
inflammation and immunotherapy.
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We aimed to elaborate on this approach, investigating clin-
ical outcomes of nasal challenge, their biological correlates,
and relationship with seasonal symptoms. We hypothesized
that patients receiving grass pollen immunotherapy would
show blunted clinical and immunological responses to nasal
challenge compared with untreated grass pollen allergics. We
describe the results of a pilot, proof-of-concept, cross-sec-
tional study.
Methods
Participants
Volunteers were recruited from the allergy clinic at the Royal
Brompton Hospital and from a database of previous study vol-
unteers. Immunotherapy-treated volunteers had a history of
grass-pollen seasonal allergic rhinitis for at least 2 years, posi-
tive skin prick (>3 mm wheal) and specific IgE (>0.70 IU/ml)
to timothy grass extract and were receiving subcutaneous or
sublingual timothy grass pollen allergen immunotherapy (Aqu-
agen SQ, Phleum pratense, 100 000 SQ-U/ml or Grazax
75 000 SQ-U; both from ALK-Abello, Hørsholm, Denmark).
Untreated allergics had the same history of symptoms and
positive skin and specific IgE tests, but no history of treatment
with allergen immunotherapy. Nonatopic controls had no his-
tory of allergic disease, negative skin prick tests to timothy
grass and other common aeroallergens, and negative specific
IgE. Exclusion criteria were perennial rhinitis, chronic or
recurrent sinusitis, current smoking or >5 pack-year history,
perennial asthma, and FEV1 <70% predicted at screening.
Participants had not used nasal corticosteroids or other anti-
allergy medications for at least 2 weeks prior to assessment.
The study was approved by the National Research Ethics Ser-
vice, London – Camberwell St Giles office, and by the
Research Office of the Royal Brompton and Harefield NHS
Foundation Trust. Written, informed consent was obtained
before study procedures were carried out.
Study design
The study consisted of two visits: a screening visit including
spirometry, skin prick testing to 12 common aeroallergens,
ImmunoCAP-specific IgE to timothy grass major allergen
Phl p5 and total IgE (Phadia/Thermo Scientific, Uppsala,
Sweden); then, for suitable candidates, a second visit for
grass pollen nasal challenge. Challenge visits were conducted
between February and April 2013, outside of the grass pollen
season. Examiners were blind to the status of the partici-
pants. On the day of the challenge, volunteers recorded their
baseline nasal symptoms according to a verified scoring sys-
tem: total nasal symptom score (TNSS) (13), a 12-point scale
with four categories: sneezing, nose running, nose blockage
and itching, each rated from 0 to 3. Additionally, the best of
three measures using a Youlten nasal peak flow meter was
recorded. Immediately afterwards, absorptive polyurethane
sponges were placed into both nostrils to collect nasal fluid.
Following this, participants underwent a nasal lavage (Si-
nusRinse; NeilMed, Santa Rosa, CA, USA). The above pro-
cedures were repeated at 30 min after lavage. A further
10 min later, participants underwent a grass pollen nasal
allergen challenge (NAC). TNSS, peak nasal inspiratory flow
(PNIF) and nasal fluid were recorded/collected at 5, 15, 30
and 60 min after challenge, then at hourly intervals to 8 h.
Between 1 and 2 h after nasal challenge, participants under-
went an intradermal injection of 1 BU (biological unit; equiv-
alent to 0.7 ng major allergen) of timothy grass extract on
the outer surface of the forearm. Wheal response was
recorded at 15 min, and late-phase infiltration at 8 h, using a
pencil-friction technique described previously (14). Addition-
ally, 15 min prior to nasal challenge, volunteers summarized
the overall severity of their symptoms during the previous
season (May–July 2012) on a retrospective 18-point scale,
with six categories: sneezing, nose running, nose blockage,
nose itching, eye itching and eye watering/redness, each rated
0–3, giving a total score of 0–18.
Nasal allergen challenge
Timothy grass pollen extract (Aquagen SQ; ALK-Abello,
Hørsholm, Denmark) was reconstituted at 100 000 SQ-U/ml
(equivalent to 30 000 BU/ml or 20.2 lg/ml major allergen) in
albumin-based diluent (ALK-Abello), before 1 in 3 dilution
in normal saline to a concentration of 33 333 SQ-U/ml
(10 000 BU/ml). Two hundred and thirty microlitres was
then added to disposable Bi-dose nasal applicator devices
(Aptar Pharma, Louveciennes Cedex, France), manufactured
to provide two 100-ll sprays. Each participant received one
100-ll spray of allergen to each nostril, applied by an exam-
iner. Participants were asked not to sniff strongly or blow
their nose in the first 5 min after allergen application.
Collection and processing of nasal fluid
A 20 9 15 9 5 mm piece of synthetic polyurethane sponge
(RG 27 grau; Gummi-Welz GmbH & Co., Neu-Ulm, Ger-
many) was inserted by an examiner into each of the volun-
teer’s nostrils, under direct vision using croc forceps and a
Thuddicum’s nasal speculum. Sponges were left in place for
2 min before removal and then added to 2-ml centrifuge
tubes with indwelling 0.22-lm cellulose acetate filters (Costar
Spin-X; Corning, Corning, NY, USA). Tubes were kept
briefly on ice before 100 ll of elution buffer [Milliplex Assay
Buffer; Millipore, Darmstadt, Germany; PBS pH 7.4, BSA
(1%), Tween-20 (0.05%), sodium azide (0.05%)] was added
on top of the sponge and the tube centrifuged at 4500 rcf at
4°C for 10 min. The isolated fluid was pipetted into Eppen-
dorf tubes and stored at 80°C.
After thawing, nasal fluid was analysed for cytokines and
chemokines using a human cytokine/chemokine magnetic
bead panel 96-well plate assay (Milliplex Map Kit; Millipore)
and a Luminex xMAP Magpix platform (Millipore), accord-
ing to the manufacturer’s instructions. Samples of 25 ll of
nasal fluid were analysed in duplicate alongside the manufac-
turer’s standards and controls. Tryptase and ECP in nasal
fluid were measured using an ImmunoCAP 100 machine
(Phadia/Thermo Scientific) according to the manufacturer’s
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instructions. Nasal fluid samples were diluted 1 in 5 in assay
diluent (ImmunoCAP IgE/ECP/Tryptase Diluent; Thermo
Scientific) and run alongside calibrators and curve controls.
Statistical analysis
A commercial software package (GraphPad Prism version
5.04 GraphPad Software, Inc., La Jolla, CA, USA) was used.
The prespecified primary outcome was the combined, equally
weighted early (0–1 h)- and late (1–8 h)-phase TNSS area
under the curve (EPR AUC + LPR AUC/7), in immunother-
apy-treated volunteers vs untreated allergics. Secondary out-
comes included the combined, equally weighted early- and
late-phase change from baseline PNIF (ΔPNIF) AUC, and
the separate early- and late-phase AUCs for TNSS and
ΔPNIF, as well as early- and late-phase skin responses to
Table 1 Demographic characteristics of participants. Results presented as median (range)
Nonatopics Untreated allergics Immunotherapy
n (M : F) 14 (5 : 9) 14 (9 : 5) 14 (6 : 8)
Age 35.5 (24 to 59) 31 (23 to 55) 38.5 (19 to 70)
Timothy grass IgE (kU/l) 0.01 (0.01 to 0.05) 9.7 (2.2 to 79.3) 28.2 (1.17 to >100)
Total IgE (kUA/l) 19.3 (<2 to 114) 138.5 (62.1 to 674) 188.5 (22.8 to 2305)
Mono : polysensitized n.a. 7 : 7 7 : 7
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Figure 1 Response to nasal allergen challenge. A, total nasal
symptom score (TNSS); B, change from baseline peak nasal inspi-
ratory flow (ΔPNIF); both mean  SE. C, TNSS per hour combined
early (EPR, 0–1 h)- and late (LPR, 1–8 h)-phase responses with
equal weighting; D, ΔPNIF per hour combined EPR and LPR; both
median and interquartile range, between-group comparisons by
Mann–Whitney U-test.
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intradermal allergen injection. Based on previous results (6),
the primary comparisons for nasal fluid mediators were made
at 8 h, with the exception of tryptase at 5 min; secondary
analyses included AUC for the full 8 h. Within-group com-
parisons were made by Wilcoxon’s matched-pairs test,
between-group comparisons by Mann–Whitney U-test and
correlations by Spearman’s rank correlation coefficient. P-
values < 0.05 were considered statistically significant.
The study was powered based on the surface area of the late-
phase skin response to intradermal allergen injection. Previous
studies (14, 15) have revealed up to 90% decrease after at least
3 months of immunotherapy compared to pretreatment
response. We calculated that inclusion of 12 participants per
group would provide 90% power to detect a 50% difference
between groups. Other outcomes were exploratory.
Results
Participant demographics
Characteristics of the 14 immunotherapy-treated volunteers,
14 untreated allergics and 14 nonatopic controls recruited are
given in Table 1. Of the 14 immunotherapy patients, six were
taking Grazax 75 000 SQ-U sublingual tablets once daily, all
for at least 6 months, and eight were receiving monthly injec-
tions of 100 000 SQ-U Aquagen SQ timothy grass pollen
extract, all having reached maintenance dose following a
standard up-dosing protocol (both from ALK-Abello; see
Table S1 in supporting information).
Clinical response to nasal allergen challenge
The immunotherapy group had reduced TNSS compared to
untreated allergics (P = 0.039, Fig. 1), particularly during the
early phase (P = 0.027, see Fig. S1 in supporting informa-
tion). Immunotherapy patients had a smaller reduction in
PNIF compared to untreated allergics (P = 0.016, Fig. 1)
and, again, most pronounced in the early phase (P = 0.014,
Fig. S1).
Local nasal biomarkers
Nasal fluid tryptase levels peaked at 5 min postchallenge.
The peak was blunted in immunotherapy patients – median
11.4 pg/ml vs 16.5 pg/ml in untreated allergics – but the dif-
ference did not reach statistical significance (P = 0.2; Fig. 2).
Nonetheless, the levels remained reduced in immunotherapy
patients at subsequent time points, narrowly missing statisti-
cal significance at 30 min (P = 0.06 vs untreated allergics;
P = 0.1, AUC comparison, 0–60 min). Eotaxin levels were
lower at 8 h in immunotherapy patients compared to
untreated allergics, 48.8 pg/ml vs 86.0 pg/ml, with a trend to
statistical significance (p = 0.08, Fig. 2 and Table S2); overall
levels across the full 8 h were significantly lower (P = 0.04,
AUC comparison).
At 8 h, nasal fluid IL-4 (P = 0.027) and IL-9 (P = 0.049)
were significantly reduced in immunotherapy patients com-
pared to untreated allergics. The levels of IL-5, IL-8, IL-10,
IL-13, MDC, RANTES and ECP were all lower at 8 h in
immunotherapy patients (Fig. 3, Tables S2 and S3), without
reaching statistical significance. AUC analysis for IL-13
revealed a trend towards lower levels across the whole 8 h
(P = 0.07).
Cutaneous allergen response
The early-phase (15 min) cutaneous wheal response to 1 BU
intradermal grass pollen allergen injection was smaller in
immunotherapy patients than in untreated allergics (27%
smaller, P < 0.0007), as was the late-phase response (51%
smaller, P < 0.0001 Fig. 4).
Retrospective seasonal symptom scores and correlations
Overall retrospective seasonal symptom scores were signifi-
cantly lower in the immunotherapy-treated group than in the
untreated allergics, median 6 vs 15 (P < 0.0001; Fig. S2).
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Figure 2 A, nasal fluid tryptase; B, nasal fluid eotaxin; both pg/ml,
median and interquartile range. †P < 0.1, untreated allergics vs
immunotherapy at 8 h, Mann–Whitney U-test.
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In untreated allergics, ΔPNIF response to NAC correlated
with seasonal symptom scores (early phase, r = 0.59,
P = 0.021; combined early and late phase, r = 0.54,
P = 0.036, Fig. S3). In the two allergic groups, overall sea-
sonal symptom scores correlated with TNSS and PNIF
responses to nasal challenge and with skin late-phase intra-
dermal allergen response (r = 0.62, P = 0.0004; r = 0.65,
P = 0.0002; and r = 0.60, P = 0.0007, respectively, Fig. S4).
Discussion
This study demonstrates the effects of grass pollen allergen
immunotherapy on responses to NAC: reduced symptoms,
improved PNIF, lower nasal fluid Th2 cytokines and chemo-
kines, plus reduced early- and late-phase cutaneous
responses. These results provide insight into the mechanisms
of specific allergen immunotherapy and suggest a possible
role for NAC as a surrogate clinical outcome in future
immunotherapy trials.
Researchers were blinded to the status of the participants
in this study. PNIF, nasal fluid biomarkers and skin
responses were objective measures and were concordant with
symptom scores. Immunotherapy-treated individuals had
equal or greater baseline grass pollen sensitization than
untreated allergics.
The cross-sectional design has limitations – selection bias,
recall bias, absence of baseline data – yet, as proof-of-con-
cept, these data are valuable, being more detailed and com-
plete than preceding studies. The inclusion of both SCIT and
SLIT patients introduced heterogeneity, as did the variable
treatment durations. Despite these limitations – which might
be expected to reduce power – we were still able to detect sig-
nificant differences between treated and untreated volunteers.
The study is underpowered for comparison between SLIT
and SCIT, but this was never the intention.
Investigators have described rapid release of tryptase (5,
16) and slower increase in Th2 cytokines/chemokines (5, 17–
20) after NAC. Similar profiles, albeit at lower magnitude,
have been described in seasonal assessments, without direct
provocation (21–23). Few studies have compared NAC with
seasonal symptoms (6), although an allergen environmental
exposure chamber has recently shown good correlation (24).
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Figure 3 A, nasal fluid IL-9; B, IL-4; C, IL-5; D, IL-13; median and interquartile range. *P < 0.05, untreated allergics vs immunotherapy, 8 h,
Mann–Whitney U-test.
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The correlations we found between seasonal symptom scores
and responses to NAC, though significant, were modest and
insufficient to make predictions on an individual basis. Con-
versely, there is no correlation between specific IgE levels and
response to nasal provocation, meaning provocation cannot
be substituted by serum testing (25). No correlations were
evident between biomarkers after NAC and seasonal symp-
toms (data not shown). It would have been ideal to include
more detailed seasonal assessments, including collection of
nasal fluid in season, to allow comparison of biomarkers
after NAC with those during natural seasonal exposure.
Previously, grass pollen immunotherapy has inhibited sea-
sonal eosinophil infiltration and reduced IL-5 mRNA in
nasal tissue (26) and also IL-5 protein in nasal fluid (11);
clinical improvement was accompanied by an increase in
local IFN-c : IL-5 mRNA ratio (27); and seasonal IL-9
mRNA was reduced alongside c-kit+ mast cells (28). The
results presented here are therefore largely in keeping with
the current literature, but extend findings to cover a broader
range of mediators in the same cohort, using noninvasive
techniques.
Immunotherapy had a predominant effect on symptoms
within the first hour after provocation. This effect on early
responses has been described previously following ragweed
immunotherapy (9). This might reflect greater biological sup-
pression of early- than late-phase mechanisms, but we saw
suppression of mediators in both phases. Conversely, the
TNSS clearly has maximum sensitivity during the early
phase, and distinct late-phase clinical responses to NAC are
only present in a minority (5, 12). This is in contrast to bron-
chial allergen provocation where late responses are easily
detected by falls in FEV1 and inhibited by allergen immuno-
therapy (29). Notably, the opposite pattern was seen in cuta-
neous allergen response, with a greater suppression of late
rather than early phase, as described previously (12).
Concerning effects of immunotherapy, there was a late (4–
8 h) suppression of Th2 cytokines, the strongest effects being
apparent with IL-4, IL-9 and eotaxin. Whilst several
researchers have demonstrated increases in peripheral blood
T-cell secretion of IL-10 in vitro following immunotherapy,
few have looked at local effects. In fact, the local IL-10
response to allergen exposure is far from clear: Pilette et al.
(30) found fewer IL-10 mRNA+ cells in the nasal mucosa of
allergics after NAC, whereas Benson et al. (21) reported
increased levels of IL-10 in nasal lavage in seasonal allergic
rhinitis. We could not detect a clear IL-10 response to nasal
challenge in nasal fluid nor an effect of immunotherapy.
Whilst ECP levels were elevated in allergics, we did not iden-
tify a significant treatment effect.
Nasal allergen provocation is convenient, allowing flexibil-
ity in comparison with seasonal assessments. There is also
likely to be lower risk of incomplete data recording and loss
to follow-up. We have identified several potential local bio-
markers of response to allergen immunotherapy – their utility
needs to be borne out in larger, prospective studies. Addi-
tionally, these techniques should be extended to perennial
allergens such as house dust mite where the relevance of
allergic sensitization to symptoms is not always obvious.
In summary, this study demonstrates that grass pollen
immunotherapy improves symptoms and peak nasal flow
after allergen challenge, associated with reductions in early-
and late-phase local inflammatory mediators. Low reactivity
to nasal provocation is associated with lower seasonal symp-
toms – hence, the model described here may be applicable as
a surrogate end point for studies of allergen immunotherapy
for seasonal allergic rhinitis.
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Figure 4 Response to intradermal injection of 1 BU purified timo-
thy grass pollen allergen at 15 min (A, early-phase response, EPR)
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als receiving sublingual immunotherapy; and triangles, subcutane-
ous immunotherapy.
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Figure S1. Response to nasal allergen challenge. A, TNSS
per hour for early-phase response (EPR, 0–1 h, area under
the curve). B, Change from baseline peak nasal inspiratory
flow (ΔPNIF) per hour for EPR. C, TNSS per hour for late-
phase response (LPR, 1–8 h). D, ΔPNIF per hour for LPR.
Median  IQR; comparisons by Mann–Whitney U-test.
Figure S2. Overall seasonal symptom score (0–18, symp-
tom-free to maximal symptoms; 0–3, in each of six catego-
ries). Individual data points, median and interquartile range;
comparisons by Mann–Whitney U-test. Squares represent
individuals receiving sublingual immunotherapy, triangles
subcutaneous immunotherapy.
Figure S3. Correlations, by Spearman’s rank correlation
coefficient, between seasonal symptom scores and change
from baseline peak nasal inspiratory flow (ΔPNIF) in the first
hour after challenge (A, EPR) and the equally weighted,
combined early- and late-phase responses (B, EPR + LPR),
in untreated atopic volunteers. AUC, area under the curve.
Figure S4. Correlations, by Spearman’s rank correlation
coefficient, between seasonal symptom scores and response to
nasal challenge. A, TNSS per hour combined, equally
weighted, early- and late-phase responses (EPR + LPR); B,
change from baseline PNIF per hour combined, equally
weighted, EPR + LPR; C, skin LPR to intradermal allergen
injection. Nonatopic patients excluded from analysis.
Table S1. Characteristics of immunotherapy-treated
patients. Results given as median (range). SCIT, subcutane-
ous allergen immunotherapy; SLIT, sublingual allergen
immunotherapy.
Table S2. Cytokines/chemokines and tryptase in nasal
fluid; median (range). *P < 0.05, †P < 0.1, untreated allergics
vs immunotherapy; all at 8 h by Mann–Whitney U-test,
except tryptase at 5 min.
Table S3. Cytokines/chemokines and ECP in nasal fluid;
median (range).
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